A young Singapore-based start-up, Aum Biosciences, is hoping to alter the general business approach for oncology R&D, which is traditionally largely US and EU-centric both in terms of development and market priorities.
Aum’s ambitious plans come against the backdrop of some startling numbers – 60% of all cancer cases in the world...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


